Sign in >>

News item: FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

Posted over 1 year ago

Continue reading...

Back to news index

Related sites from Google



Send feedback about this page
Email a link to this page

This topic elsewhere

Loading...
Loading...